- IzoView Breast CT targets aggressive market displacement with up to 67% lower pricing than competing breast CT systems, positioning at $500K versus competitors priced up to $1.5 million
- True 360-degree 3D imaging without compression positioned to bridge the clinical gap between standard screening and MRI, offering 100x greater spatial resolution than MRI at significantly lower cost
- Platform approach enables 14 potential future indications across screening, diagnosis, monitoring, and treatment planning through software upgrades, creating scalable revenue expansion without hardware replacement
Every year, outdated imaging technologies underperform for the roughly half of women undergoing breast cancer screening who have dense breast tissue. Dense breast tissue creates a fundamental imaging challenge in compression-based imaging, like mammography, where overlapping structures can mask cancers, potentially delaying diagnosis when cancers are small and in their most treatable stages. This limitation represents an $8 billion annual burden in follow-up procedures, repeat imaging, and unnecessary interventions driven by inconclusive results from current screening technologies.
Izotropic (CSE: IZO) (OTCQB: IZOZF) is developing this type of transformational approach through its IzoView Breast CT Imaging System, designed to disrupt established imaging categories through…
NOTE TO INVESTORS: The latest news and updates relating to IZOZF are available in the company’s newsroom at ibn.fm/IZOZF
About BioMedWire
BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.
BMW is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)
For more information, please visit https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer
BioMedWire
San Francisco, CA
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is powered by IBN
